ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2135

Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation

Anne C. Bay-Jensen1, Steven B. Abramson2, Jonathan Samuels3, Inger Byrjalsen4, Svetlana Krasnokutsky Samuels5, Tina Manon-Jensen6, Morten Asser Karsdal1 and Mukundan Attur7, 1Rheumatology, Nordic Bioscience, Herlev, Denmark, 2Rheumatology Research, NYU School of Medicine and NYU Hospital for Joint Diseases, New York, NY, 3Department of Medicine, NYU School of Medicine, NYU Langone Medical Center, New York, NY, 4Nordic Bioscience, Clinical Development, Herlev, Denmark, 5Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, 6Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 7Rheumatology Research, NYU - Hospital for Joint Diseases, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, Inflammation, osteoarthritis and pain

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Biology and Pathology of Bone and Joint - Poster I

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Osteoarthritis (OA) is a disease characterized by pain and tissue destruction, in some cases concomitant with inflammation. The link between pain and tissue destruction is yet unknown, and there is a lack objective quantifiable parameters. Collagens are the main structural proteins of the joint extracellular matrix. The degradation of especially type I (connective tissue), II (cartilage), III (synovium) and IV (basement membrane) collagens have been shown to be elevated in OA. So we investigated whether biomarkers reflecting collagen degradation were associated with knee OA representing with different pain and inflammatory phenotypes.

Methods:  111 knee OA patients, 62% women, from NYUHJD progression cohort study with varying degree of OA were included: mean (SD) age, 62 (10); mean(SD) BMI, 27(4); NSAID users, 23%; radiographic OA (KL≥2) 68%; and bilateral knee OA; 87%. Pain was assessed by VASpain and WOMAC at baseline (BL) at a 2-year follow-up (FU) visit. Median (IQR) were 39 (13-69) and 37 (13-52) for BL VASpain and WOMACpain. 4 BL serum biomarkers of type I, II, III and IV collagen degradation (C1M, C2M, C3M, C4M), and the 2 inflammatory biomarkers CRPM and hsCRP, were assessed. Data were log2 transformed. Associations between BL biomarkers, BL pain and change (CHG) pain scores were assessed by multivariate linear model including gender, age, BMI, KLsignal knee, bilateral knee OA and NSAID use. Patients with cont. mild/moderate pain had a BL VASpain<54 and FU VASpain<30, cont. moderate/severe pain had VASpain>30 at baseline and FU, and transitional severe pain had either VASpain_BL<30 and VASpain_FU>54 or VASpain_BL>54 and VASpain_FU<30 (ref). Patients with; low biochemical disease activity index (bDAI) low in CRPM (<12nM) moderate bDAI were high in CRPM but low in hsCRP (<5), and high bDAI (flare) were high in CRPM and hsCRP.

Results:  BL association between pain and biomarkers C2M (β -17.9, p<0.0001) and KLsignal knee (β -5.4, p=0.0031) were significantly associated with WOMAC pain. C2M (β -12.4, p=0.0033), C3M (β -19.9, p=0.059), age (β -0.84, p<0.0018), KLsignal knee (β 8.9, p=0.0021) and bilateral knee OA (β -12.2, p=0.087) were associated with VASpain. Association between BL biomarkers and CHG pain C2M (β 13.3, p=0.0016), age (β 0.5, p=0.029) and bilateral OA (β -12.0, p=0.043) were significantly associated with delta WOMACpain. Only age, BMI and NSAID use was associated with CHG VASpain. Association between pain phenotypes and BL biomarkers Patients with cont. mild/moderate pain had significantly higher C2M compared patients with transitional severe pain (p=0.0014) and cont. moderate/severe pain (p=0.04). Biomarker, BL pain and CHG pain in patients w. inflammatory OA Patient with low bDAI had lower WOMACpain (p<0.05) and VASpain(p<0.1). C1M was higher (p<0.05) in the flare group compared to the low and moderate bDAI groups. C3M was higher (p<0.05) in the moderate bDAI group than the low DAI group.

Conclusion:  Different collagen degradation products are linked differentially to different phenotypes. Cartilage degradation (C2M) was consistently linked to CHG pain phenotypes, whereas it was not associated with an inflammatory phenotype. In contrast, C1M and C3M were linked to inflammatory and flared OA.


Disclosure: A. C. Bay-Jensen, Nordic Bioscience A/, 1,Nordic Bioscience A/S, 3,D-BOARD, 2; S. B. Abramson, None; J. Samuels, None; I. Byrjalsen, Nordic Bioscience A/S, 3; S. Krasnokutsky Samuels, None; T. Manon-Jensen, None; M. A. Karsdal, Nordic Bioscience A/S, 1,Nordic Bioscience A/S, 3; M. Attur, None.

To cite this abstract in AMA style:

Bay-Jensen AC, Abramson SB, Samuels J, Byrjalsen I, Krasnokutsky Samuels S, Manon-Jensen T, Karsdal MA, Attur M. Knee Osteoarthritis Pain Is Differentially Associated with Tissue Degradation and Joint Inflammation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/knee-osteoarthritis-pain-is-differentially-associated-with-tissue-degradation-and-joint-inflammation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/knee-osteoarthritis-pain-is-differentially-associated-with-tissue-degradation-and-joint-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology